Gilgamesh Pharmaceuticals
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $101M
Investors
- 11
About Gilgamesh Pharmaceuticals
Founded in 2019, Gilgamesh Pharmaceuticals focuses on creating new chemical entities (NCEs) aimed at curing psychiatric disorders. In March 2026, Gilgamesh Pharmaceuticals, Inc. The leadership team includes co-founders Dalibor Sames, Jonathan Sporn (CEO), and Andrew Kruegel (CSO). Gilgamesh Pharmaceuticals specializes in developing innovative new chemical entities (NCEs) aimed at transforming the treatment landscape for psychiatric disorders. Their core product offerings focus on rapid-acting therapies designed to address conditions such as depression, anxiety, and opioid use disorder. These therapeutics are characterized by their oral bioavailability, optimized duration of effect, and improved safety profiles, particularly with fewer dissociative effects compared to existing treatments. Targeting both clinicians and patients, Gilgamesh's products are intended for markets primarily in North America and Europe, where there is a significant demand for advanced mental health solutions that move beyond traditional symptom management. The company's commitment to collaboration with pharmaceutical partners and research institutions bolsters its position in the biotech sector, emphasizing its role in pioneering effective therapies. Gilgamesh Pharmaceuticals operates through a transaction structure that includes partnerships with pharmaceutical companies and research institutions, facilitating the development and distribution of its products. Revenue generation is driven by milestone payments, licensing agreements, and potential royalties from successful product launches. While specific pricing plans for their flagship products are not disclosed, the company’s focus on providing rapid and sustained efficacy in its offerings underscores its strategic positioning within the mental health market.
Who invested in Gilgamesh Pharmaceuticals
11 investors across 6 rounds
See all investors in Gilgamesh Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gilgamesh Pharmaceuticals
Who invested in Gilgamesh Pharmaceuticals?
Gilgamesh Pharmaceuticals has 11 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gilgamesh Pharmaceuticals raised?
Gilgamesh Pharmaceuticals has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Gilgamesh Pharmaceuticals last raise money?
Gilgamesh Pharmaceuticals's most recent round on record is a Series A, in Mar 2026.
What does Gilgamesh Pharmaceuticals do?
Founded in 2019, Gilgamesh Pharmaceuticals focuses on creating new chemical entities (NCEs) aimed at curing psychiatric disorders.
Where is Gilgamesh Pharmaceuticals headquartered?
Gilgamesh Pharmaceuticals is headquartered in New York, US.
Which VCs invest in companies like Gilgamesh Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Gilgamesh Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Gilgamesh Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.